Technology evaluation: VEGF Trap (cancer), Regeneron/sanofi-aventis

Sin C. Lau; Daniela D. Rosa; Gordon Jayson

Technology evaluation: VEGF Trap (cancer), Regeneron/sanofi-aventis

Sin C. Lau
, Daniela D. Rosa
, Gordon Jayson

Research output: Contribution to journal › Article › peer-review

Abstract

Sanofi-aventis (formerly Aventis) and Regeneron are developing systemic VEGF Trap, a soluble decoy receptor comprising portions of VEGF receptors 1 and 2, for the potential intravenous/subcutaneous treatment of cancer. © The Thomson Corporation.

Original language	English
Pages (from-to)	493-501
Number of pages	8
Journal	Current Opinion in Molecular Therapeutics
Volume	7
Issue number	5
Publication status	Published - Oct 2005

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

therapeutic use: Angiogenesis Inhibitors
Animals
Clinical Trials, Phase I
Drug Evaluation, Preclinical
Humans
Mice
blood supply: Neoplasms
antagonists & inhibitors: Vascular Endothelial Growth Factor A
metabolism: Vascular Endothelial Growth Factor Receptor-1
metabolism: Vascular Endothelial Growth Factor Receptor-2

Cite this

@article{8165f7fad3164933a46f415aa508e4bd,

title = "Technology evaluation: VEGF Trap (cancer), Regeneron/sanofi-aventis",

abstract = "Sanofi-aventis (formerly Aventis) and Regeneron are developing systemic VEGF Trap, a soluble decoy receptor comprising portions of VEGF receptors 1 and 2, for the potential intravenous/subcutaneous treatment of cancer. {\textcopyright} The Thomson Corporation.",

keywords = "therapeutic use: Angiogenesis Inhibitors, Animals, Clinical Trials, Phase I, Drug Evaluation, Preclinical, Humans, Mice, blood supply: Neoplasms, antagonists \& inhibitors: Vascular Endothelial Growth Factor A, metabolism: Vascular Endothelial Growth Factor Receptor-1, metabolism: Vascular Endothelial Growth Factor Receptor-2",

author = "Lau, \{Sin C.\} and Rosa, \{Daniela D.\} and Gordon Jayson",

year = "2005",

month = oct,

language = "English",

volume = "7",

pages = "493--501",

journal = "Current Opinion in Molecular Therapeutics",

issn = "1464-8431",

publisher = "Thomson Scientific Ltd.",

number = "5",

}

TY - JOUR

T1 - Technology evaluation: VEGF Trap (cancer), Regeneron/sanofi-aventis

AU - Lau, Sin C.

AU - Rosa, Daniela D.

AU - Jayson, Gordon

PY - 2005/10

Y1 - 2005/10

N2 - Sanofi-aventis (formerly Aventis) and Regeneron are developing systemic VEGF Trap, a soluble decoy receptor comprising portions of VEGF receptors 1 and 2, for the potential intravenous/subcutaneous treatment of cancer. © The Thomson Corporation.

AB - Sanofi-aventis (formerly Aventis) and Regeneron are developing systemic VEGF Trap, a soluble decoy receptor comprising portions of VEGF receptors 1 and 2, for the potential intravenous/subcutaneous treatment of cancer. © The Thomson Corporation.

KW - therapeutic use: Angiogenesis Inhibitors

KW - Animals

KW - Clinical Trials, Phase I

KW - Drug Evaluation, Preclinical

KW - Humans

KW - Mice

KW - blood supply: Neoplasms

KW - antagonists & inhibitors: Vascular Endothelial Growth Factor A

KW - metabolism: Vascular Endothelial Growth Factor Receptor-1

KW - metabolism: Vascular Endothelial Growth Factor Receptor-2

M3 - Article

SN - 1464-8431

VL - 7

SP - 493

EP - 501

JO - Current Opinion in Molecular Therapeutics

JF - Current Opinion in Molecular Therapeutics

IS - 5

ER -

Technology evaluation: VEGF Trap (cancer), Regeneron/sanofi-aventis

Abstract

UN SDGs

Keywords

Fingerprint

Cite this